[go: up one dir, main page]

AR130361A1 - Cocristales derivados de crisaborol - Google Patents

Cocristales derivados de crisaborol

Info

Publication number
AR130361A1
AR130361A1 ARP230102322A ARP230102322A AR130361A1 AR 130361 A1 AR130361 A1 AR 130361A1 AR P230102322 A ARP230102322 A AR P230102322A AR P230102322 A ARP230102322 A AR P230102322A AR 130361 A1 AR130361 A1 AR 130361A1
Authority
AR
Argentina
Prior art keywords
derived
cocrystals
crysaborol
chrysaborole
acid
Prior art date
Application number
ARP230102322A
Other languages
English (en)
Inventor
Guilherme Savoi
Original Assignee
Guilherme Savoi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilherme Savoi filed Critical Guilherme Savoi
Publication of AR130361A1 publication Critical patent/AR130361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C07D213/67—2-Methyl-3-hydroxy-4,5-bis(hydroxy-methyl)pyridine, i.e. pyridoxine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona nuevos cocristales derivados (co-fórmeros: Cafeína, Ácido Picolínico, Ácido Quináldico y Piridoxina) de 4-((1-hidroxi-1,3-dihidrobenzo[c][1,2]oxaborol-5-il)oxi)benzonitrilo (Crisaborol) que tienen propiedades de disolución variadas cuando se comparan con el Crisaborol libre.
ARP230102322A 2022-09-01 2023-08-31 Cocristales derivados de crisaborol AR130361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263403025P 2022-09-01 2022-09-01

Publications (1)

Publication Number Publication Date
AR130361A1 true AR130361A1 (es) 2024-11-27

Family

ID=90099010

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102322A AR130361A1 (es) 2022-09-01 2023-08-31 Cocristales derivados de crisaborol

Country Status (2)

Country Link
AR (1) AR130361A1 (es)
WO (1) WO2024047571A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447506B2 (en) * 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
JP2019520321A (ja) * 2016-05-09 2019-07-18 アナコール ファーマシューティカルズ，インコーポレイテッド フリー体のクリサボロールの結晶形ならびにそれらの調製方法および使用
WO2017203514A1 (en) * 2016-05-26 2017-11-30 Perrigo Api Ltd Polymorphs of crisaborole and production processes therefor
US20170305936A1 (en) * 2016-07-12 2017-10-26 Pliva Hrvatska D.O.O. Solid state forms of crisaborole
US10865217B2 (en) * 2017-05-23 2020-12-15 Msn Laboratories Private Limited, R & D Center Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
US10329311B1 (en) * 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
US10597410B2 (en) * 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
IT201800002347A1 (it) * 2018-02-02 2019-08-02 Dipharma Francis Srl Intermedi e procedimento per la preparazione di una forma cristallina di un farmaco antiinfiammatorio topico
CN112375093A (zh) * 2020-11-13 2021-02-19 江苏知原药业股份有限公司 一种克立硼罗晶型化合物及其制备方法
CN113087733A (zh) * 2021-04-06 2021-07-09 南京科默生物医药有限公司 克立硼罗的晶型a、晶型b、晶型c、晶型d、晶型e及其制备方法

Also Published As

Publication number Publication date
WO2024047571A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
MX390520B (es) Suministro de agente soluble en surfactante.
MX2020014144A (es) Composicion anticaspa en aerosol con bajo contenido de surfactante.
ZA202401398B (en) Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
PE20151994A1 (es) Modificador del sabor dulce
PE20001242A1 (es) N-[4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il]-acrilamida, un inhibidor irreversible de las cinasas de la tirosina
TNSN03084A1 (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
MX361488B (es) Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk).
MY138341A (en) Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
MX2021008295A (es) Formas sólidas que comprenden (s)-4-(4-(4-(((2-(2,6-dioxopiperidin -3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fl uorobenzonitrilo y sales del mismo, composiciones que comprenden y métodos de utilización del mismo.
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
PH12021551967A1 (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
EA201890886A1 (ru) Композиция для отбеливания кожи
CR8889A (es) Derivados de n-(1h-indolil)- 1h-indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica
EA201691139A1 (ru) Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты и полиоксиэтиленовое касторовое масло
BR112018001816A2 (pt) “análogos de adamantil ureias como inibidores solúveis da epóxido hidrolase
FR3042710B1 (fr) Composition a base de dihydromyricetine et d'un sel de zinc pour le traitement de l'acne et des peaux grasses
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
AR130361A1 (es) Cocristales derivados de crisaborol
EP4438127A3 (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
JOP20190129B1 (ar) تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين
UY29903A1 (es) Dialurea para el tratamiento de la hipertension pulmonar
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain

Legal Events

Date Code Title Description
FB Suspension of granting procedure